Noa Therapeutics, a preclinical Canadian biotech company aiming to defy the convention of traditional drug development to revolutionize treatment options for those living with complex inflammatory skin diseases, has received the Women Entrepreneur $5,000 grant at the CanWIN 2024 Bridge to Asia Pitch competition.
Noa Therapeutics is an OBIO® member, alumnus of our BDSP™, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.